Armata Pharmaceuticals has spent more than a decade engineering pathogen-specific bacteriophage cocktails and is now standing on the threshold of the first registrational study of its lead asset, AP-SA02, against complicated Staphylococcus aureus bacteremia. The interim disclosure for the second quarter of 2026, filed on August 12, 2026, frames the company in transition rather than terminal: an intravenous phage candidate that received Fast Track designation in May, a fully negotiated Phase 3 superiority protocol, and a fresh $25 million term loan from principal stockholder Innoviva arrived in the same quarter, but management also disclosed that current cash is not sufficient to fund the next twelve months of operations, raising substantial doubt about the company's ability to continue as a going concern unless further capital is raised.
The headline financial print looks paradoxical. The quarterly statement of operations reports net income of approximately $74.1 million for the three months ended June 30, 2026, against a net loss of $16.3 million in the comparable 2025 quarter, but almost the entire swing is non-cash. A $91.0 million gain from the mark-to-market re-measurement of the company's $30 million convertible loan drove the result, offset by $6.6 million of interest expense; on a diluted basis the company posted a $0.27 loss per share because the convertible loan is anti-dilutive in a profitable quarter. Stripping that mark-to-market artifact out, the operating loss widened year over year from approximately $6.8 million to $10.3 million as research and development rose to $7.6 million and general and administrative jumped to $5.2 million, almost entirely on higher non-cash stock-based compensation following option grants issued after the second quarter of 2025.
The trade is binary on the Phase 3 initiation, not on the print. The diluted share count of roughly 62 million, the $0.27 loss per share on a diluted basis, and the $24.0 million of unrestricted cash together describe a microcapitalization clinical-stage biotech in which the equity is priced as the option value of a single registrational program; the load-bearing question is whether Armata can fund that program to its interim analysis without an additional dilutive round, given the disclosed going-concern qualification, the high-coupon Innoviva debt stack, and a DoW award that funds a fraction of Phase 3 readiness rather than the trial itself.